Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)

1. Mora-Rodríguez, J.M.
2. Sánchez, B.G.
3. Bort, A.
4. Díaz-Yuste, A.
5. Ballester-González, R.
6. Arrieta, F.
7. Sebastián-Martín, A.
8. Díaz-Laviada, I.